Puma reports interim Phase III ExteNET trial results of PB272 to treat HER2-positive breast cancer

US-based biopharmaceutical company Puma Biotechnology has reported interim 5-year disease free survival data from the Phase III ExteNET trial of PB272 (neratinib) for an adjuvant treatment of early stage, HER2-positive breast cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news